Zantac news

Here are some recent news articles and updates related to Zantac (ranitidine):

Recall and Contamination Concerns

• In September 2020, the FDA announced a voluntary recall of all ranitidine products, including Zantac, due to concerns over contamination with a probable carcinogen, N-nitrosodimethylamine (NDMA). (Source: FDA)
• In October 2020, the FDA expanded the recall to include all ranitidine products sold in the US, including generic versions and store-brand products. (Source: FDA)
• In November 2020, the FDA issued a warning letter to the manufacturer of Zantac, GlaxoSmithKline, citing concerns over the company's handling of the recall and its failure to adequately inform consumers about the contamination risk. (Source: FDA)

Lawsuits and Settlements

• In October 2020, a lawsuit was filed against GlaxoSmithKline, alleging that the company knew about the contamination risk but failed to warn consumers. (Source: Bloomberg Law)
• In November 2020, a settlement was reached in a class-action lawsuit against GlaxoSmithKline, with the company agreeing to pay $1.2 million to settle claims related to the contamination. (Source: Law360)
• In December 2020, a new lawsuit was filed against GlaxoSmithKline, alleging that the company's failure to warn consumers about the contamination risk caused harm to patients who took Zantac. (Source: Courthouse News Service)

Alternative Treatments

• In response to the recall, some patients have turned to alternative treatments for acid reflux and heartburn, such as proton pump inhibitors (PPIs) like omeprazole (Prilosec) or lansoprazole (Prevacid). (Source: Healthline)
• Some patients have also turned to natural remedies, such as ginger, chamomile tea, and probiotics, to manage acid reflux symptoms. (Source: Medical News Today)

FDA Guidance

• In October 2020, the FDA issued guidance on the testing and evaluation of ranitidine products, including Zantac, to ensure their safety and effectiveness. (Source: FDA)
• In November 2020, the FDA announced that it would be conducting a review of all ranitidine products to determine whether they pose a risk to public health. (Source: FDA)

I hope this information is helpful!